Board of Directors
- Stephen A. Sherwin, M.D.
- Jeffrey M. Ostrove, Ph.D.
- David Mack, Ph.D.
- Dennis Henner, Ph.D.
- John Walker
- Stephen M. Simes
- Kerry Dance, Ph.D.
Board of Directors
Stephen A. Sherwin, M.D.
Co-founder & Chairman, Board of Directors
Dr. Sherwin was formerly the Chairman of the Board and Chief Executive Officer of Cell Genesys, Inc., positions he held until the company was merged with Biosante Pharmaceuticals in October, 2009. He served as Chief Executive Officer since the company began operations in 1990, and as Chairman of the Board since 1994. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., most recently as Vice President, Clinical Research. Prior to 1983 he was on the staff of the National Cancer Institute. Dr Sherwin currently serves as a Director of Biosante Pharmaceuticals, Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc. He was a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen, Inc. in 2006. Dr. Sherwin has been a member of the Board of Directors of the Biotechnology Industry Organization since 2002 and was elected Chairman of the Board in 2009. Dr. Sherwin received his B.A. in biology from Yale University and his M.D. from Harvard Medical School. He is board certified in internal medicine and medical oncology.
Jeffrey M. Ostrove, Ph.D.
President & Chief Executive Officer
Prior to joining Ceregene as its first employee in April 2001, Dr. Ostrove was Chief Operating Officer of NeuroVir Therapeutics, Inc. located in Vancouver, B.C. and San Diego, CA and was instrumental in its merger with Medigene AG. Preceding NeuroVir (Medigene), Dr. Ostrove served as Senior Vice President and Chief Scientist of MAGENTA Corporation of Rockville, Maryland, a company he founded as a subsidiary of BioReliance, Inc. where he was also Vice President for Scientific Development. Dr. Ostrove also served on the staff of the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health. Dr. Ostrove holds a Ph.D. in molecular biology from the University of Florida College of Medicine and completed his post-doctoral training at The Johns Hopkins University School of Medicine.
David Mack, Ph.D.
Director, Alta Partners
Dr. Mack joined Alta in 2002. Prior to Alta, he co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. Dr. Mack was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s. He has co-authored more than 30 scientific articles and reviews including papers published in Cell, Science and Nature, and is an inventor on 21 US patents. Dr. Mack was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in microbiology and immunology. He received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes Fellow in molecular genetics and cell biology. Dr. Mack holds a B.A. in molecular biology from the University of California, Berkeley.
Dennis Henner, Ph.D.
General Partner, MPM BioVentures III
Prior to joining MPM, Dr. Henner was at Genentech from 1981 to 2001. He was the Senior Vice President of Research at Genentech and a member of the Executive Committee, Product Review Committee and Research Review Committee. During his tenure, he oversaw the development of numerous products that have been fundamental to the success of Genentech including novel antibody products such as Herceptin. Dr. Henner is currently Director of Tercica, Rinat Neuroscience, Synergia, Ceregene and Kalobios. His scientific work focused on the expression of therapeutic proteins in bacterial hosts, and the development of recombinant antibody therapeutics. Dr. Henner received his Ph.D. in microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
Board Director John Walker is currently the CEO of iPierian. Most recently, Mr. Walker served as Chairman and CEO of Novacea, which merged with Transcept Pharmaceuticals in January 2009. Mr. Walker has also been Executive Chairman and Principal Executive Officer of Renovis Inc.; Chairman and Interim CEO of Guava Technologies, KAI Pharmaceuticals and Centaur Pharmaceuticals; and Chairman and CEO of Bayhill Therapeutics. From 1993 to 2001, he was Chairman and CEO of Arris Pharmaceuticals and its successor corporation AXYS Pharmaceuticals Inc., and previously was Chairman and CEO of Vitaphore Corporation. Mr. Walker began his career with American Hospital Supply Corporation, where he last served as President of the American Hospital Company. His many board experiences have included serving as Chairman of Signal Pharmaceuticals and Microcide Pharmaceuticals Inc., and a Director of Geron Corporation, Discovery Partners Inc., and several other private companies. Mr. Walker received a B.A. from the State University of New York at Buffalo and is a graduate of the Advanced Executive Program, J. L. Kellogg Graduate School of Management at Northwestern University. He currently serves on the Board of Directors of Affymax, Inc., Transcept Pharmaceuticals, Inc., and a couple of private companies.
Stephen M. Simes
President & CEO, BioSante Pharmaceuticals, Inc.
Mr. Simes has been Vice Chairman, President & CEO of BioSante Pharmaceuticals, Inc. since January 1998. Prior to BioSante, Mr. Simes was President & CEO of Unimed Pharmaceuticals, Inc. and Gynex Pharmaceuticals, Inc., both of which were sold to bigger companies; Unimed to Solvay and Gynex to Bio-Technology General Corp. (now Savient Pharmaceuticals, Inc.). Mr. Simes started his career in the pharmaceutical industry with G.D. Searle & Co. in 1974. Since 1984, he has specialized in emerging companies, building product portfolios in endocrinology, urology, hormones and drug delivery systems, among other areas. Mr. Simes holds a B.S. in chemistry from Brooklyn College of the City University of New York and an M.B.A. from New York University.
Kerry Dance, Ph.D.
Managing Director, Hamilton BioVentures
Dr. Dance has 25 years of executive experience, both as a scientist and a leader, and has focused on life sciences since the formation of Hamilton BioVentures in 2000. Dr. Dance came to San Diego in 1978 and was President of General Atomics Corporation. While at General Atomics he founded an in-house venture enterprise which produced a successful track record and spun off several successful enterprises, including the San Diego Super Computer Center. Dr. Dance is currently the Chairman of the Board of Directors of Angstrom Pharmaceuticals and is a Director of PhotoThera. He was a founding Board Member of Egea Biosciences and was actively involved in direction of the company as well as its sale to J&J in 2004. He has previously served as CEO of Advanced Distillation Technology, a seawater desalination company, as well as President of the S-Cubed Division of Maxwell Laboratories, Inc., and Vice President of Technology for Aerojet General Corporation. Dr. Dance received his Ph.D. from Stanford University.